Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cu-Cyclam is a coordination complex consisting of a copper(II) ion chelated by the macrocyclic ligand cyclam (1,4,8,11-tetraazacyclotetradecane). Cyclam is a 14-membered tetraamine macrocycle that binds strongly to transition metal ions such as copper. The Cu-Cyclam complex has been studied primarily as an experimental agent and is not approved for clinical use. Its main interest lies in its ability to form highly stable complexes with copper(II), which can be exploited for various biomedical applications including radiopharmaceuticals (e.g., PET imaging agents using radioactive isotopes like ^64Cu), targeted cancer therapy (as in αVβ3 integrin-targeted radionuclide therapy), and as model compounds for studying redox processes and metalloprotein mimics[1][3][6]. Mechanistically, Cu-Cyclam may interact with biological targets such as lysozyme C but its precise pharmacological action remains unclear[1]. The stability of the Cu-cyclam complex makes it useful in nuclear medicine and diagnostic imaging[7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cu-cyclam.